ASCO 2026 is a wrap, and we needed an extra week to digest it all! Here the review list:1. RASolute 302 - daraxonrasib and its standing ovation2. MajesTEC-9 - 2L teclistamab in multiple myeloma in patient population 100% exposed to CD-38 targeting drugs3. Initsmeran autogene + pembrolizumab in resected melanoma. Only a Phase 2 study, but super promising and exciting use of personalized medicine using mRNA technology4. Libretto-043 - adjuvant selpercatinib in RET-fusion positive NSCLC following resection and platinum-based chemotherapy (in most of these patients)5. PROTEUS - meh6. SARC041 - Phase study of abemaciclib vs. placebo in dedifferntiated liposarcoma. The placebo did very poorly7. CROWN at 7-years continues to offer an enticing PFS plateau with lorlatinib use in advanced ALK rearrangement+ NSCLCThe Learning Oncology Companion from KelleyCPharmD:https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm